TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01813162
Drug: Vaginal product
Normalized name: Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02199184
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02199184
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00425802
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01161277
Drug: Placebo sugar pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 1-2 pills depending on subject weight
Study: NCT03430284
Drug: Pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy is individualized. 1.Glucose-lowering agents:~1. Oral antihyperglycemic agents:Biguanides;Sulfonylureas;Thiazolidinediones;Glinides;a-Glucosidase inhibitors;DPP-4 inhibitors;Sodium-glucose cotransporter 2 inhibitors~2. GLP-1 receptor agonist~3. Insulin:Rapid-acting analogs;Short-acting analogs;Intermediate-acting analogs;Basal insulin analogs;Premixed insulin products~2.Blood pressure-lowering agents~(1)ACE inhibitor;(2)Angiotensin receptor blockers (ARBs);(3)Calcium channel blockers (CCB);(4)Diuretics;(5)β-blockers;(6)α1-blockers~3.Lipid-modifying agents~(1)Statins;(2)Fibrates;(3)Others: Nicotinic Acid, Ezetimibe,Probucol,Bile Acid Sequestrants,Policosanol,etc.~4.Medications for weight management~(1)Glucose-lowering agents associated with weight loss;(2)Orlistat;(3)Metabolic Surgery~The above medications are individualized to maintain the risk factors (blood glucose, serum lipid profiles, blood pressure and weight) at appropriate levels.
Study: NCT00497081
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 30 mg daily for 3 months
Study: NCT03631251
Drug: Open Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
Study: NCT02098785
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution
Study: NCT02956226
Drug: Cannabinoids - 99% pure cannabinoids mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
Study: NCT02481674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
Study: NCT02956226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil and flavors solution.
Study: NCT02956226
Drug: Cannabinoids - whole plant extract
Normalized name: century plant whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
Study: NCT01006785
Drug: DLBS1425
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 150 mg daily for 12 - 16 weeks of treatment
Study: NCT01006785
Drug: DLBS1425
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 300 mg daily for 12 - 16 weeks of treatment
Study: NCT03469557
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be treated with capecitabine 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
Study: NCT00002715
Drug: Stanford V regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002715
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A component of the Stanford V regimen.
Study: NCT03911401
Drug: 0.3% OPA-15406
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT03911401
Drug: 1% OPA-15406
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT03911401
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT04638543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02345447
Drug: Herbal-based medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aconitum napellus, Capsicum annuum; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum; Hydrastis canadensis; Iodum; Natrium tetraboracicum; Sambucus nigra; Sanguinaria canadensis
Study: NCT02345447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous ethanol solution non-distinguishable from verum
Study: NCT00368069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets, 2 tablets once daily
Study: NCT00399542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00635193
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
Study: NCT02225626
Drug: Other: standard breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
Study: NCT04772456
Drug: Hyperpolarized 13C-Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[ 13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, malignancy.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, that refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\].
Study: NCT04322890
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg, ivgtt, every 21day.
Study: NCT04088149
Drug: GXNPC1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous ADSCs
Study: NCT04097938
Drug: GLPG3667 oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3667 oral suspension
Study: NCT04097938
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral suspension
Study: NCT04097938
Drug: GLPG3667 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3667 capsules
Study: NCT02582775
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3
Study: NCT00551694
Drug: GSK256073A tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03707249
Drug: Ferric Carboxymaltose Injectable Product
Normalized name: ferric carboxymaltose Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv iron infusion: 15 mg / kg up to a maximum 1g dose of Ferinject diluted in normal saline (0.9%) up to a total volume of 250 ml
Study: NCT03707249
Drug: Normal Saline 0.9% Infusion Solution Bag
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml of normal (0.9%) saline given by intravenous infusion over 20 minutes. This constitutes the control for the iron infusion.
Study: NCT03969004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion over 30 minutes
Study: NCT03467750
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group will receive 0.5mg/kg of ketorolac, administered intravenously.
Study: NCT03467750
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.~A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.~The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered.
Study: NCT03094468
Drug: P-3058 (terbinafine hydrochloride 10%)
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will apply the P-3058 nail solution once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
Study: NCT03094468
Drug: Vehicle of P-3058
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will apply the Vehicle of P-3058 once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
Study: NCT00796367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00617942
Drug: Cohort 2 neo-adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
Study: NCT00617942
Drug: Cohort 1 adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
Study: NCT00617942
Drug: Cohort 2 adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
Study: NCT01263652
Drug: Diclofenac hydroxyethylpyrrolidine
Normalized name: diclofenac hydroxyethylpyrrolidine 1.292 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM/PO
Study: NCT00526214
Drug: celecoxib medication
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
Study: NCT02350868
Drug: MPT0E028
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
Study: NCT01467531
Drug: GSK1265744
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg q24h
Study: NCT04409262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV placebo matched to TCZ
Study: NCT02500732
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo capsule designed to blind the atomoxetine intervention
Study: NCT04401813
Drug: IBI308 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received IBI310 combined with sintilizumab 200mg
Study: NCT04504253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (dextrose 5mg) matched to creatine monohydrate loose powder
Study: NCT03970746
Drug: Keytruda Injectable Product
Normalized name: Keytruda Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intention and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%) must have been made by the investigator before and regardless of the patient's participation in the study.
Study: NCT03970746
Drug: Alimta Injectable Product
Normalized name: Alimta Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients with non-squamous NSCLC included in Cohorts A1 and A2, maintenance by pemetrexed (IV every 3 weeks) can be administered according to SoC.
Study: NCT04223479
Drug: Probiotic Formula Capsule
Normalized name: Probiotic Formula Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Probiotic will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 6 weeks.
Study: NCT04223479
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Placebos will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the placebo every 2 weeks and will be followed weekly for 6 weeks.
Study: NCT02386475
Drug: sinemet plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
Study: NCT01294319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01294319
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01294319
Drug: Combined
Normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00943566
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
Study: NCT04501874
Drug: EMB-001 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive comparator
Study: NCT01593761
Drug: CG400549
Approvals — FDA: no, EMA: no, PMDA: no
Description: 960mg QD at fed state approx 1 hour after meal
Study: NCT01965600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 0 mg, TID, 3 days, 1 of 2 periods
Study: NCT01965600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 0 mg, BID, 3 days, 1 of 2 periods
Study: NCT03313297
Drug: AZD4017
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4017 is a novel orally bioavailable small molecule inhibitor of 11β-HSD1 enzyme activity. It is potent and highly selective in vitro and in vivo. The half maximal inhibitory concentration (IC50) for inhibition of 11β-HSD1 activity (cortisone to cortisol conversion) is 2nM. AZD4017 is selective (\> 2000x) for 11β-HSD1 over human recombinant 11β-HSD2 and the closely-homologous enzymes 17β-hydroxysteroid dehydrogenase 1 and 17β-hydroxysteroid dehydrogenase 3 in vitro.
Study: NCT03313297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01156636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00387621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.
Study: NCT04227678
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: an intravenous (i.v.) heparin bolus (50 IU/kg i.v.) followed by 250 IU/h i.v. during 6 hours, starting 15 minutes before ingestion of liquid meal
Study: NCT04046029
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
Study: NCT04762810
Drug: Cyclophosphamide and glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months. Cyclophosphamide 50mg per day for 6 months and decrease to 50mg Qod for 6 months.
Study: NCT04762810
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids have fast onset of action and multiple anti-inflammatory effects. Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less than 5mg per day in 6 months.
Study: NCT03493464
Drug: BR55
Normalized name: Band-Aid Ourtone BR55 Bandages
Approvals — FDA: no, EMA: no, PMDA: no
Description: A novel targeted ultrasound contrast agent
Study: NCT04146259
Drug: calcium carbonate and alphacalcidol
Normalized name: calcium acetate and magnesium carbonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment for hypocalcemia
Study: NCT02451137
Drug: Background Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
Study: NCT01034345
Drug: Calcineurin inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.
Study: NCT02944604
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06593730
Drug: NRL001 cream 0.5%w/w
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06593730
Drug: NRL001 cream 0.75%w/w
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06593730
Drug: NRL001 cream 1.0%w/w
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06593730
Drug: NRL001 cream 1.5%w/w
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06593730
Drug: NRL001 cream 2.0%w/w
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06593730
Drug: NRL001 cream 2.5%w/w
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04300556
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone administered orally.
Study: NCT01832753
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04392531
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care according to hospital protocol
Study: NCT03616652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill
Study: NCT02885506
Drug: Oral administration of P218 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.
Study: NCT02889861
Drug: IMCgp100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bispecific soluble human leukocyte antigen-A2 (HLA-A2) restricted gp100-specific TCR fused to anti-CD3
Study: NCT00911508
Drug: Rate or Rhythm Control Therapy
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg~Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg
Study: NCT03846466
Drug: KHK4323 IV/S
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV / Single administration
Study: NCT03846466
Drug: KHK4323 SC/S
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC / Single administration
Study: NCT03846466
Drug: KHK4323 IV/M
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV / Multiple administration
Study: NCT03846466
Drug: Placebo IV/S
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV / Single administration
Study: NCT03846466
Drug: Placebo IV/M
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV / Multiple administration
Study: NCT03846466
Drug: Placebo SC/S
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC / Single administration
Study: NCT03648021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mL of chlorure de sodium 0.9% administred intravenously. 1 dose
Study: NCT00001426
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00207831
Drug: Tegafur and Uracil
Normalized name: Tegafur and uracil only product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04835142
Drug: Double blind control period A140
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: experiment arm： Drug A140:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv), Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h) control arm: Drug Erbitux:400 mg/m2（D1，iv）,250 mg/m2（qw，iv） Drug Oxaliplatin 85 mg/m2（D1,iv) Drug Calcium Folinate 400 mg/m2（D1,iv） Drug 5-FU 400 mg/m2（D1,iv），2400 mg/m2 (48±4h)
Study: NCT02335359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT02111473
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone 250 mg injection per 3-4 weeks for 6 months
Study: NCT01519700
Drug: EP2006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will be teated with EP2006
Study: NCT01958944
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03375788
Drug: Identical Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection daily
Study: NCT02337543
Drug: NEO6860
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEO6860 is an NCE acting as a TRPV1 antagonist